{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:13:02Z","timestamp":1790118782015,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.lungcan.2017.04.019","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T05:45:57Z","timestamp":1493271957000},"page":"42-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report"],"prefix":"10.1016","volume":"109","author":[{"given":"Takeshi","family":"Uenami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Ishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kanazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.04.019_bib0005","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/archderm.1977.01640040029001","article-title":"Should vitiligo be induced in patients after resection of primary melanoma","volume":"113","author":"Lerner","year":"1977","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0015","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.1978.03280390079031","article-title":"Vitiligo. What is it? Is it important?","volume":"239","author":"Lerner","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2017.04.019_bib0020","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1001\/archopht.1978.03910060461015","article-title":"Iritis in patients with cutaneous melanoma and vitiligo","volume":"96","author":"Albert","year":"1978","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0030","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","article-title":"Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy","volume":"19","author":"Rosenberg","year":"1996","journal-title":"J. Immunother. Emphas. Tumor Immunol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.annder.2013.01.442","article-title":"Pigmentary disorders induced by anticancer agents. Part II: targeted therapies","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann. Dermatol. Venereol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0045","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.lungcan.2017.04.019_bib0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1755-148X.2010.00703.x","article-title":"First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi","volume":"23","author":"van Geel","year":"2010","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0055","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1523-1747.2003.12413.x","article-title":"Cytotoxic T lymphocyte reactivity to gp100, MelanA\/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients","volume":"121","author":"Mandelcorn-Monson","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0065","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","article-title":"Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo","volume":"192","author":"Yee","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0075","doi-asserted-by":"crossref","first-page":"44173","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0080","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.04.019_bib0085","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1182\/blood-2012-04-427013","article-title":"Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8T cells","volume":"120","author":"Tewalt","year":"2012","journal-title":"Blood"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T09:29:22Z","timestamp":1535880562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217303069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":17,"alternative-id":["S0169500217303069"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.019","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}